E.Cruz-HerreraJ.Perez-TorresE.Abdo-FrancisJ
Many of the hitherto applied inhibitors of G6PDH contain sugar phosphates or various nucleotides competing with the substrate (G6P) or cofactor (NADP + ), respectively (for review see 7 )
Fluvoxamine Maleate [who-dd] 63
Several new therapeutic approaches aimed at slowing the progression of PD are considered disease-modifying treatments and include anti-inflammatory agents (selnoflast, azatriopine), antioxidants, agents that stimulate mitochondrial function, agents that increase glucocerebrosidase activity (ambroxol), agents that activate the glucagon-like peptide-1 receptor (exenatide, lixisenatide, Peptron), agents that block specific kinase activity (SPARCs K0706, Inhibikases IKT148009, and Il-Yangs radotinib), agents that reduce or inhibit LRRK2 activity (BIIB122), drugs that target GI tract activity (rifaximin), and molecules that prevent -syn aggregation or disaggregation of existing complexes (prasinezumab, memantine, buntanetap)
doi: 10.1128/jb.128.1.192-201.1976 120 HellerJ
